Loading...
•
Dec 31, 2024
Seer Q4 2024 Earnings Report
Seer reported its fourth quarter and full year 2024 financial results.
Key Takeaways
Seer reported a 10% decrease in Q4 2024 revenue to $4.0 million compared to the prior year, primarily due to lower instrument sales and no grant revenue. The company ended the year with approximately $300 million in cash, cash equivalents, and investments.
Achieved revenue of $4.0 million for the fourth quarter of 2024.
Shipped 10 instruments during 2024, bringing cumulative instruments shipped to 72.
Launched a new product application for the Proteograph XT workflow for cell lysis proteomics.
Repurchased approximately 6.5 million shares of Class A common stock, reducing shares outstanding by about 10%.
Revenue by Segment
Forward Guidance
Seer expects full year 2025 revenue to be in the range of $17 million to $18 million, representing growth of 24% at the midpoint over full year 2024.
Positive Outlook
- Expected revenue growth of 24% at the midpoint for FY 2025.
- Continued validation of differentiated value of deep, unbiased proteomics at scale.
- Growing momentum despite challenging macroeconomic environment.
- Surge in customer publications and strong demand for STAC.
- Expanded partnership with Thermo Fisher Scientific to accelerate adoption of Proteograph Product Suite.
Challenges Ahead
- No specific negative guidance points were provided in the report.
- The company did not provide specific guidance on profitability for 2025.
- No specific guidance on operating expenses for 2025.
- No specific guidance on cash flow for 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...